New findings suggest addiction is biologically complex, supporting harm reduction strategies grounded in neuroscience rather than stigma.
With few exceptions, nicotine has been defined for decades as little more than a chemical hook — a substance whose addictive properties alone account for the millions of people who can’t stop smoking. But contemporary addiction science is presenting a much more complex picture. New genetic and neurobiological studies prove that vulnerability to heavy smoking and nicotine addiction in general, is not the same for everyone. Brain support cells actively participate in dependence, and nicotine’s attractiveness may be linked as much to stress control as to reward. For advocates of tobacco harm reduction, these findings bolster a basic truth: Addiction is complicated and solutions need to cater for these possible different causes.
A gene impacting nicotine addiction
One of the most exciting developments in nicotine addiction comes from a large genomic analysis appearing in Nature Communications. The researchers analysed almost 38,000 smokers in the Mexico City Prospective Study. They discovered a variation in the gene CHRNB3, which helps build part of the brain receptors that respond to nicotine. People with this gene variant tended to smoke far fewer cigarettes.
These receptors (acetylcholine) are key to nicotine’s psychoactive effects. When nicotine attaches to them, the feel-good neurotransmitter dopamine is released — a fact that reinforces use. But genetic variation seems to tone down that response. Those who carried a copy of the CHRNB3 variant smoked about 21 percent fewer cigarettes each day than those without it. Those with two copies smoked about 78 percent less.
Crucially, the association was not limited to just one population. The conclusions were replicated among a similar number of participants, about 130,000 of European ancestry in the UK Biobank and around 180,000 of East Asian ancestry in Biobank Japan.
Naturally, more work is necessary to elucidate the impact of these variants on the severity of dependence, but the initial data demonstrate that specific genetic haplotypes act as biological brakes on smoking behaviour across a wide range of populations. And of course the implications are profound. If changes in certain receptor subunits lead to decreased cigarette smoking, pharmacological approaches that modulate this pathway could potentially reduce nicotine dependence. Instead of assuming all smokers have equal susceptibility, future treatments may target specific biological pathways.
A new angle to tackle smoking cessation
No less attention-getting, is a new line of preclinical investigation from Pusan National University. This particular study is turning the spotlight away from neurons, long seen as addiction’s primary movers and shakers, to astrocytes, the brain’s supportive glial cells.
In a study led by Professor Eun Sang Choe, researchers found that repeated exposure to nicotine activates specific receptors, called α7 nicotinic acetylcholine receptors, on astrocytes in a part of the brain known as the caudate–putamen. When these receptors are switched on, calcium enters the cells and triggers a chain reaction involving a stress-related protein. This process increases the activity of an enzyme known as glutamine synthetase, which speeds up a key brain chemical cycle. As a result, the animals in the study showed a stronger behavioural response to nicotine.
To find out if this brain pathway really mattered, researchers injected a substance designed to block the connection between two key proteins involved in nicotine’s effects. The results were striking. The enzyme’s activity dropped sharply, and the animals showed a much weaker response to nicotine.
This study adds to growing evidence that addiction is complex and multifaceted. By identifying this enzyme as an important part of nicotine’s effects, the research points to a possible new treatment approach — one that focuses not on nicotine itself, but on how repeated exposure changes the brain.
The relationship between nicotine, stress, and self-regulation
These biological findings overlap with another cluster of research.
While nicotine is unquestionably addictive, addiction doesn’t happen in a vacuum. Many smokers find that smoking helps them cope with anxiety, enhance focus or stabilise mood during times of stress; some even claim that a cigarette is the only thing which will help them relax. Experimental studies have found that nicotine may temporarily improve attentional capacity and perceived stress during the gradual development of long-term dependence.
From a neurobiological perspective, nicotine activates reward-related dopamine pathways as well as acetylcholine and glutamate systems related to cognitive function. For those living stressful lives, nicotine’s temporary stabilising effects may lead to repeated use. This implies an important reframing — if stress relief is one of the properties that makes nicotine reinforcing, then decreasing exposure to stressors or focusing on improving people’s coping mechanisms could certainly break the cycle of dependence more than prohibition.
Theories that promote the resilience of our individual behaviours and workplace interventions in mental health, as well as larger community-building policies, can also be included to identify ways to reduce smoking rates. Crucially, this approach is also consistent with harm reduction principles. If people are using nicotine partly to self-medicate stress, removing access to lower-risk alternatives without addressing underlying stresses might push them back toward combustible cigarettes — the delivery form of nicotine responsible for the vast majority of tobacco-related disease.
Combustion, not nicotine, is what policy should focus on
The public health disaster that is smoking arises not from the nicotine itself, but rather from combustion. Nicotine keeps smokers hooked, but the smoke is what kills. This distinction is important as emerging evidence points to genetic variability and brain adaptability. If certain people are biologically inclined to smoke less heavily, and specific receptor pathways or astrocytic enzymes can be targeted therapeutically, then nicotine policy should focus on reducing harm in the future — not levelling all products toward a single risk profile.
Alternative smoke-free products that do not involve combustion, like vapes, heated tobacco and nicotine pouches, are used to consume nicotine. Not risk-free, they vastly reduce exposure to toxins. And for highly dependent smokers, especially those who don’t carry protective genetic variants, these options hold a significant opportunity to reduce harm.
Different factors give us more options to address addiction
The intersection between genetics, brain biology and stress suggests one simple fact: nicotine addiction is multifactorial, and future cessation approaches should reflect this. For the tobacco harm reduction movement, these results emphasise that the regulatory response must be proportionate and grounded in scientific nuance. A one-size-fits-all approach to restrictions that ignores differences in risk or individual vulnerability does not tackle the complexity of addiction. Policies that facilitate adult access to lower-risk nicotine products, but maintain investment in research and smoking cessation efforts, are what actually make sense.
Thankfully, addiction science is evolving. But public health strategies should change too. Moving away from moral panic towards evidence-based harm reduction that meets people where they are, reduces exposure to combustion, and addresses the deeper drivers of dependence.